Pancreatic carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Overall, our study showed that ITGB4 and its phosphorylated form promote cell migration and invasion in pancreatic cancer and that p-ITGB4-Y1510 regulates the downstream MEK1-ERK1/2 signaling cascades.
|
31242404 |
2020 |
Pancreatic carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
A total of 6 ATO target genes (namely AKT1, CCND1, CDKN2A, IKBKB, MAPK1 and MAPK3) were found to be associated with pancreatic cancer.
|
31612027 |
2019 |
Pancreatic carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
However, no studies have shown the expression of ERK1/2 on pancreatic stromal and its effect on pancreatic cancer-stromal interaction.
|
31133044 |
2019 |
Pancreatic carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Inhibiting MEK1/ERK1/2 pathway with sorafenib could improve the cytotoxity of HHT in vitro and in a genetically engineered mouse model of pancreatic cancer.
|
29665121 |
2018 |
Pancreatic carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Further mechanism related studies demonstrated that ERK1/2-ZEB1 pathway-triggered epithelial-mesenchymal transition (EMT) might be responsible for the PIK3R3-induced PC cell migration and invasion.
|
29719293 |
2018 |
Pancreatic carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Oncogenic HSP60 regulates mitochondrial oxidative phosphorylation to support Erk1/2 activation during pancreatic cancer cell growth.
|
29415987 |
2018 |
Pancreatic carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
In this study, JQ1 and I-BET 762 decreased c-Myc and p-Erk 1/2 protein levels and inhibited proliferation in pancreatic cancer cells.
|
28254412 |
2017 |
Pancreatic carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Nerve growth factor regulates CD133 function to promote tumor cell migration and invasion via activating ERK1/2 signaling in pancreatic cancer.
|
27654574 |
2017 |
Pancreatic carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
The mechanism by which p-ERK1/2 and HIF-1α affect ABCG2s expression was analyzed in the hypoxic cultured human pancreatic cancer cell line Capan-2.
|
26785721 |
2016 |
Pancreatic carcinoma
|
0.100 |
PosttranslationalModification
|
disease |
BEFREE |
We assessed the level of DcR3 protein and ERK1/2 phosphorylation in tumor and non-tumor tissue samples of 66 patients with pancreatic carcinoma.
|
26102031 |
2015 |
Pancreatic carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Targeting the ERK1/2-Bax/Bcl-2 pathway may in part lead to sensitization of pancreatic cancer to gemcitabine.
|
25880226 |
2015 |
Pancreatic carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
It was concluded that miR-424-5p is frequently upregulated in pancreatic cancer and modulates ERK1/2 signaling pathway by negatively regulating SOCS6.
|
23653113 |
2013 |
Pancreatic carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Also in contrast to HPDE cells, ethanol did not attenuate ERK1/2 phosphorylation in pancreatic cancer cells; however, inhibiting ERK1/2 decreased pancreatic cancer cell invasion.
|
21678462 |
2011 |
Pancreatic carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
These in vitro characteristics translated to increased tumor growth in both subcutaneous and orthotopic pancreatic cancer murine models and also led to increased liver metastasis. mTrop2 expression also increased the levels of phosphorylated ERK1/2 mediating cell cycle progression by increasing the levels of cyclin D1 and cyclin E as well as downregulating p27.
|
20858281 |
2010 |